← Back to guidelines
Cardiology23 papers

Glucagonoma, malignant

Last edited: 4/16/2026

Overview

Glucagonoma is a rare neuroendocrine tumor characterized by excessive glucagon production, leading to a constellation of symptoms including diabetes mellitus, weight loss, and a characteristic rash known as necrolytic migratory erythema 1.

Diagnosis

  • Elevated plasma glucagon levels 1.
  • Identification of glucagon-secreting tumors through imaging (e.g., CT, MRI) 1.
  • Chromatographic analysis may reveal genuine glucagon rather than larger immunoreactive forms 1.
  • Absence of overt diabetes or hyperglycemia despite elevated glucagon levels 1.
  • Management

  • Surgical resection of the tumor when feasible 1.
  • Supportive care including glucose monitoring and management 1.
  • No specific drug doses mentioned for glucagonoma management in the provided abstracts 1.
  • Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.
  • Key Recommendations

  • Confirm diagnosis through elevated plasma glucagon levels and imaging to identify the source tumor (Evidence: Moderate) 1.
  • Prioritize surgical intervention for localized tumors to achieve potential cure (Evidence: Expert opinion) 1.
  • Manage metabolic complications symptomatically, focusing on glucose control without specific pharmacological interventions detailed in the abstracts (Evidence: Expert opinion) 1.
  • References

    1 Torre L, Vazquez JA, Blázquez E. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma. Hormone research 1986. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG